<DOC>
	<DOC>NCT00774761</DOC>
	<brief_summary>The purpose of this study is to evaluate the systemic exposure and pharmacodynamics of two doses of nebulized fluticasone/formoterol combination as compared to the monocomponents.</brief_summary>
	<brief_title>A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Able to understand the requirements of the study and provide consent Medical diagnosis of COPD A current or prior history of at least 10pack years of cigarette smoking Female of childbearing potential to use adequate birth control Diagnosis of asthma Other significant disease than COPD Has donated a unit of blood within 30 days of study, or intends to donate QTc greater than 0.460 seconds Subjects who had radiation or chemotherapy in the previous 12 months Subjects who had lung resection History of illegal drug abuse or alcohol abuse within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Obstructive</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>